Extrait

Phase I: To determine the recommended dose of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12 (+2) q4W Phase II: To determine the antitumour activity of CP-4055 in patients with platinum resistant ovarian cancer according to Response Criteria in Solid Tumors RECIST and Gynecologic Cancet Intergroup (CGIG) CA-125 measurements

Critère d'inclusion

• A phase I/II clinical study of CP4055 in patients with platinum resistant ovarian cancer

Liens

• ictrp
• euctr